Revolution Medicines, Inc.
RVMD
$203.71
$1.710.85%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 76.20% | 67.18% | 56.80% | 72.98% | 66.11% |
| Gross Profit | -76.20% | -67.18% | -56.80% | -72.98% | -66.11% |
| SG&A Expenses | 171.59% | 189.20% | 136.35% | 120.21% | 86.91% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 90.82% | 84.92% | 67.18% | 79.42% | 68.99% |
| Operating Income | -90.82% | -84.92% | -67.18% | -79.42% | -68.99% |
| Income Before Tax | -160.05% | -112.64% | -86.82% | -95.28% | -85.98% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -160.05% | -112.64% | -87.54% | -95.28% | -85.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -160.05% | -112.64% | -87.54% | -95.28% | -85.98% |
| EBIT | -90.82% | -84.92% | -67.18% | -79.42% | -68.99% |
| EBITDA | -91.21% | -85.23% | -67.46% | -79.92% | -69.68% |
| EPS Basic | -132.54% | -101.97% | -65.69% | -72.19% | -62.85% |
| Normalized Basic EPS | -132.54% | -101.97% | -65.04% | -72.16% | -62.87% |
| EPS Diluted | -132.54% | -101.97% | -65.69% | -72.19% | -62.85% |
| Normalized Diluted EPS | -132.54% | -101.97% | -65.04% | -72.16% | -62.87% |
| Average Basic Shares Outstanding | 11.83% | 5.29% | 13.19% | 13.42% | 14.19% |
| Average Diluted Shares Outstanding | 11.83% | 5.29% | 13.19% | 13.42% | 14.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |